Koninklijke Philips (PHG) AI Stock Analysis

• Market Cap: $26.57B
• Dividend Yield: 3.3%
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): 24.8
• Beta (1Y): 0.88
• Revenue Growth: -0.76%
• EPS Growth: -55.03%
• Country: US
• Employees: 67,247
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.71
• Shares Outstanding: 962,920,100
• 10 Day Avg. Volume: 918,911
• 30 Day Avg. Volume: 1,147,459
• PEG Ratio: -0.11
• Price to Book (P/B): 2.02
• Price to Sales (P/S): 1.24
• P/FCF Ratio: 24.84
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 1.60
• Enterprise Value/Gross Profit: 3.55
• Enterprise Value/Ebitda: 10.85
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.8
• Revenue Forecast (FY): $21.20B

• Rating: 64 Neutral
• Price Target: $30.00 ▲(0.67% Upside)
• Action: Reiterated Date: 02/12/26
• Date: Action: Reiterated 02/12/26

PHG scores as moderately attractive, led by a clear 2025 profitability recovery and a supportive technical uptrend. The score is capped by multi-year earnings and cash-flow volatility and meaningful 2026 headwinds (tariffs and Respironics-related uncertainty), while the ~3% dividend provides some valuation support despite a negative P/E.

Positive Factors

Installed-base recurring revenue

Philips’ business model benefits from an installed‑base flywheel: strong aftermarket services, software and consumables attachment create recurring revenue that cushions capital‑equipment cyclicality, improves revenue visibility and supports long‑term margin resilience.

Productivity and cost savings

Sustained, material productivity delivery (over EUR2.5bn since 2023 with continued programs) structurally raises operating leverage potential, funds reinvestment and margin targets, and provides a durable mechanism to offset cost headwinds and support cash generation.

Innovation and strategic M&A

A deep innovation pipeline and targeted M&A expand clinical capabilities and product mix (MRI, spectral CT, AI navigation, intravascular imaging), strengthening competitive differentiation, enabling premium pricing and supporting sustainable revenue and gross‑margin improvement over time.

Negative Factors

Respironics legal/regulatory risk

The Respironics recall and attendant regulatory probes create persistent legal, compliance and remediation costs, elevate reputational risk, and necessitate ongoing quality investments. These factors can drive multi‑year cash outflows and constrain operating focus and growth.

Tariff-driven margin pressure

Sustained tariff exposure (EUR250–300m annualized) materially compresses margins unless fully mitigated, forcing pricing, localization or cost actions. It reduces margin carry‑through on growth and increases execution risk for multi‑year profitability targets.

Volatile free cash flow

Free cash flow has shown large swings driven by one‑offs and settlements, weakening predictability of internal funding for capex, R&D and dividends. This volatility raises refinancing and allocation risk and complicates delivery of multi‑year targets without continued non‑recurring relief.

Koninklijke Philips Business Overview & Revenue Model

Company Description

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes Money

Philips makes money mainly by selling healthcare technology products and by providing recurring services and software tied to those products. A significant portion of revenue comes from capital equipment sales to hospitals and healthcare providers (e.g., diagnostic imaging systems, image-guided therapy systems, and patient monitoring equipment). In addition, Philips generates revenue from aftermarket and recurring sources such as service contracts (maintenance, repairs, lifecycle management), software and informatics offerings (including licenses/subscriptions where applicable), upgrades, and replacement parts/consumables required to operate and maintain installed systems. This mix typically creates an installed-base flywheel: once equipment is deployed, Philips can earn ongoing revenue through service agreements, software, and periodic system upgrades over the equipment’s life. Philips’ earnings are influenced by factors such as hospital capital spending cycles, the size and utilization of its installed base, multi-year service/managed-services arrangements, and the company’s ability to attach service and software to equipment sales. Specific, material partnerships or counterparty arrangements contributing to earnings are not available in the provided context and are therefore null.

Koninklijke Philips Financial Statement Overview

Summary

Financials are improving but still volatile: 2025 returned to profitability with better gross and operating margins, and leverage appears manageable. However, results swung from strong profit (2021) to sizable losses (2022–2024), and cash flow has been uneven with a sharp free-cash-flow decline in 2025 versus 2024.

Income Statement

Profitability has improved meaningfully versus the loss-making period in 2022–2024, with 2025 returning to positive earnings (about 5.0% net margin) and stronger operating profitability than 2024. Gross margin also improved to ~45% in 2025 from ~43% in 2024 and ~40% in 2022–2023. However, revenue has been broadly flat across 2020–2024 and only rebounded in 2025, and the last several years show notable volatility (large losses in 2022–2024 versus strong profit in 2021), which lowers overall quality and consistency.

Balance Sheet

Leverage looks manageable for the sector, with debt-to-equity around 0.74 in 2025 (generally ~0.55–0.62 in 2022–2024), suggesting moderate balance-sheet risk. Equity remains substantial, though it has trended down from 2021–2022 levels, indicating some erosion in the capital base over time. Returns on equity have recovered to ~8% in 2025 after being negative in 2022–2024, but the recent history of negative returns highlights that profitability still needs to prove durability.

Cash Flow

Cash generation is positive in recent years, with 2025 producing operating cash flow of ~$1.16B and free cash flow of ~$0.89B, and free cash flow covering roughly three-quarters of net income. That said, cash flow has been volatile (including negative operating and free cash flow in 2022), and 2025 free cash flow declined sharply versus 2024 (negative growth). Operating cash flow relative to revenue also appears modest versus prior years, suggesting working-capital or cash-conversion pressures.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	17.83B	18.02B	18.17B	17.83B	17.16B
Gross Profit	8.06B	7.77B	7.45B	7.19B	7.17B
EBITDA	2.64B	1.85B	1.04B	115.00M	2.00B
Net Income	895.00M	-702.00M	-466.00M	-1.61B	3.32B
Balance Sheet
Total Assets	26.94B	28.98B	29.41B	30.69B	30.96B
Cash, Cash Equivalents and Short-Term Investments	2.79B	2.40B	1.87B	1.18B	2.31B
Total Debt	8.09B	7.49B	7.29B	7.34B	6.05B
Total Liabilities	15.96B	16.93B	17.34B	17.41B	16.49B
Stockholders Equity	10.96B	12.01B	12.03B	13.25B	14.44B
Cash Flow
Free Cash Flow	893.00M	1.35B	1.94B	-648.45M	1.46B
Operating Cash Flow	1.16B	1.70B	2.31B	-181.82M	1.93B
Investing Cash Flow	-737.00M	-633.87M	-553.53M	-1.58B	-317.95M
Financing Cash Flow	107.00M	-536.52M	-916.79M	525.49M	-2.77B

Koninklijke Philips Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHG, the sentiment is Negative. The current price of 29.8 is below the 20-day moving average (MA) of 30.44, below the 50-day MA of 29.83, and above the 200-day MA of 27.36, indicating a neutral trend. The MACD of -0.45 indicates Positive momentum. The RSI at 34.29 is Neutral, neither overbought nor oversold. The STOCH value of 6.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHG.

Koninklijke Philips Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	77 Outperform	$24.72B	30.97	32.44%	―	14.21%	5.66%
BSX	68 Neutral	$102.58B	48.91	12.53%	―	21.62%	54.80%
SYK	67 Neutral	$128.88B	41.38	15.04%	0.95%	10.95%	-18.32%
PHG	64 Neutral	$26.57B	24.78	8.21%	3.30%	-0.76%	-55.03%
ABT	62 Neutral	$187.72B	33.55	12.89%	1.88%	6.37%	142.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SSKN	46 Neutral	$1.53M	-14.23	-476.74%	―	-5.19%	-0.81%

Koninklijke Philips Corporate Events

Royal Philips Files 2025 Annual Report Highlighting Growth, Cash Generation and ESG Progress

On February 19, 2026, Koninklijke Philips N.V. filed a Form 6-K with the U.S. Securities and Exchange Commission to furnish its 2025 Annual Report and related press release to investors. The report, prepared under IFRS and Dutch market rules, details audited group and company financial statements, ESG metrics and governance disclosures, formally placing Philips’ 2025 performance and risk profile on the record for regulators and shareholders.

The 2025 Annual Report highlights EUR 17.8 billion in sales, 2% comparable sales growth, a 12.3% adjusted EBITA margin and EUR 512 million in free cash flow despite cost pressures and tariffs. Philips reports that it improved the lives of 2 billion people, including 253 million in underserved communities, derived 27.9% of sales from circular products and continued strengthening quality, patient safety and operational foundations as part of its multi‑year turnaround.

Additional 2025 milestones include being ranked the highest medtech company in Clarivate’s Top 100 Global Innovators and expanding access to care through long-term partnerships such as in Indonesia. The company also underscored innovation in areas like helium-free 3.0T MRI and AI-powered diagnostic tools, while its CEO emphasized that visible operational gains in 2025 are intended to support sustainable, profitable growth and long-term value creation for stakeholders.

The most recent analyst rating on (PHG) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Koninklijke Philips stock, see the PHG Stock Forecast page.

Philips Moves to Extend CEO Roy Jakobs’ Mandate as Profitable Growth Strategy Advances

Royal Philips said on February 10, 2026, that it will propose the re-appointment of Roy Jakobs as President and CEO and as a member of the Board of Management at its May 8, 2026 annual general meeting. The move signals the Supervisory Board’s desire for continuity in leadership as the company pursues its next phase of profitable growth in the global health technology market.

The Supervisory Board cited progress since 2022, including addressing the Respironics recall, strengthening a culture of patient safety and quality, simplifying the organization and delivering €2.5 billion in productivity savings. It also highlighted restored growth, higher margins, positive cash generation and a stronger balance sheet, underscoring confidence that Jakobs can sustain operational improvements and long-term value creation for shareholders and other stakeholders.

The most recent analyst rating on (PHG) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Koninklijke Philips stock, see the PHG Stock Forecast page.

Philips Posts Strong Q4 2025, Lifts Margins and Cash Flow as It Sets 2026–2028 Growth Targets

Philips reported its full-year and fourth-quarter 2025 results on February 10, 2026, showing a 6% rise in comparable order intake for the year and 7% in the fourth quarter, with 2025 group sales of EUR 17.8 billion and 2% comparable sales growth, accelerating to 7% in the final quarter. Income from operations reached EUR 1,424 million for 2025, while the adjusted EBITA margin expanded by 80 basis points to 12.3% for the year and 160 basis points to 15.1% in Q4, supported by productivity gains that offset higher tariffs and underpinned solid cash generation.

Free cash flow for 2025 came in at EUR 512 million, including a EUR 1,025 million payment related to Respironics recall settlements in the U.S., while Q4 free cash flow surged to EUR 1,200 million, contributing to what management called a robust balance sheet. All main segments grew in the fourth quarter, with Connected Care and Personal Health delivering notable sales and margin improvements and Diagnosis & Treatment stabilizing margins despite tariff pressure, as Philips completed a three-year EUR 2.5 billion productivity program.

Operationally, Philips highlighted strong momentum in innovation and strategic partnerships, including the launch of helium-free 3.0T MR and AI-powered imaging platforms, new enterprise-scale patient monitoring solutions, and the acquisition of SpectraWAVE, signed in December 2025 and closed in January 2026, which broadens its coronary intervention portfolio. New long-term agreements with large U.S. healthcare providers for monitoring and cloud-based imaging IT, along with locally tailored consumer health launches in China, underscore Philips’ push to deepen its presence in key markets and support AI-enabled clinical workflows.

At its Capital Markets Day, Philips set 2026–2028 financial targets, aiming for a mid-single-digit comparable sales CAGR and a mid-teens adjusted EBITA margin by 2028, anchored in segment-specific growth strategies, innovation-led expansion, and continued disciplined execution. The company also proposed a 2025 dividend of EUR 0.85 per share and introduced updated 2030 impact ambitions, signaling to investors a focus on profitable growth, sustained productivity, and integrated sustainability goals after a three-year period of operational strengthening and quality remediation.

The most recent analyst rating on (PHG) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Koninklijke Philips stock, see the PHG Stock Forecast page.